These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 25800510

  • 1. Bisphosphonates in juvenile dermatomyositis with dystrophic calcinosis.
    Tayfur AC, Topaloglu R, Gulhan B, Bilginer Y.
    Mod Rheumatol; 2015 Jul; 25(4):615-20. PubMed ID: 25800510
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of the treatment with intravenous pamidronate in calcinosis in juvenile dermatomyositis.
    Marco Puche A, Calvo Penades I, Lopez Montesinos B.
    Clin Exp Rheumatol; 2010 Jul; 28(1):135-40. PubMed ID: 20346254
    [Abstract] [Full Text] [Related]

  • 3. Recovery of Severe Muscular and Fascial Calcinosis After Treatment With Bisphosphonates in a Child With Juvenile Dermatomyositis.
    Cañas CA, Bonilla-Abadía F, Mejía M, Tobón GJ.
    J Clin Rheumatol; 2015 Aug; 21(5):267-9. PubMed ID: 26203832
    [Abstract] [Full Text] [Related]

  • 4. Improvement of calcinosis using pamidronate in a patient with juvenile dermatomyositis.
    Martillotti J, Moote D, Zemel L.
    Pediatr Radiol; 2014 Jan; 44(1):115-8. PubMed ID: 23839717
    [Abstract] [Full Text] [Related]

  • 5. Complete and sustained resolution of calcinosis universalis in a juvenile dermatomyositis case with mycophenolate mofetil.
    Çakan M, Karadağ ŞG, Ayaz NA.
    Turk J Pediatr; 2019 Jan; 61(5):771-775. PubMed ID: 32105011
    [Abstract] [Full Text] [Related]

  • 6. Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate.
    Slimani S, Abdessemed A, Haddouche A, Ladjouze-Rezig A.
    Joint Bone Spine; 2010 Jan; 77(1):70-2. PubMed ID: 20031471
    [Abstract] [Full Text] [Related]

  • 7. Calcinosis in juvenile dermatomyositis: frequency, risk factors and outcome.
    Saini I, Kalaivani M, Kabra SK.
    Rheumatol Int; 2016 Jul; 36(7):961-5. PubMed ID: 27007612
    [Abstract] [Full Text] [Related]

  • 8. Assessment, classification and treatment of calcinosis as a complication of juvenile dermatomyositis: a survey of pediatric rheumatologists by the childhood arthritis and rheumatology research alliance (CARRA).
    Orandi AB, Baszis KW, Dharnidharka VR, Huber AM, Hoeltzel MF, CARRA Juvenile Myositis subgroup.
    Pediatr Rheumatol Online J; 2017 Sep 21; 15(1):71. PubMed ID: 28934971
    [Abstract] [Full Text] [Related]

  • 9. [A case of juvenile dermatomyositis with calcinosis universalis--remarkable improvement with aluminum hydroxide therapy].
    Aihara Y, Mori M, Ibe M, Kuriyama T, Takahashi Y, Shimizu C, Shike H, Mitsuda T, Yokota S.
    Ryumachi; 1994 Oct 21; 34(5):879-84. PubMed ID: 7801200
    [Abstract] [Full Text] [Related]

  • 10. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis.
    Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP.
    J Am Acad Dermatol; 2002 Oct 21; 47(4):505-11. PubMed ID: 12271292
    [Abstract] [Full Text] [Related]

  • 11. Juvenile-onset clinically amyopathic dermatomyositis: an overview of recent progress in diagnosis and management.
    Walling HW, Gerami P, Sontheimer RD.
    Paediatr Drugs; 2010 Oct 21; 12(1):23-34. PubMed ID: 20034339
    [Abstract] [Full Text] [Related]

  • 12. The presentation, assessment, pathogenesis, and treatment of calcinosis in juvenile dermatomyositis.
    Hoeltzel MF, Oberle EJ, Robinson AB, Agarwal A, Rider LG.
    Curr Rheumatol Rep; 2014 Dec 21; 16(12):467. PubMed ID: 25366934
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis.
    Nakamura H, Kawakami A, Ida H, Ejima E, Origuchi T, Eguchi K.
    J Rheumatol; 2006 Aug 21; 33(8):1691-3. PubMed ID: 16881125
    [Abstract] [Full Text] [Related]

  • 14. Clinical features, treatments and outcomes of calcinosis in adult patients with dermatomyositis: a single cohort study.
    Jiang W, Yang H, Li S, Tian X, Wang G.
    Rheumatology (Oxford); 2021 Jun 18; 60(6):2958-2962. PubMed ID: 33249499
    [Abstract] [Full Text] [Related]

  • 15. Juvenile dermatomyositis-associated calcinosis successfully treated with combined immunosuppressive, bisphosphonate, oral baricitinib and physical therapy.
    Agud-Dios M, Arroyo-Andres J, Rubio-Muñiz C, Zarco-Olivo C, Calleja-Algarra A, de Inocencio J, Perez SIP.
    Dermatol Ther; 2022 Dec 18; 35(12):e15960. PubMed ID: 36286617
    [No Abstract] [Full Text] [Related]

  • 16. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study.
    Okong'o LO, Esser M, Wilmshurst J, Scott C.
    Pediatr Rheumatol Online J; 2016 Nov 11; 14(1):60. PubMed ID: 27835954
    [Abstract] [Full Text] [Related]

  • 17. Age-dependent inhibition of ectopic calcification: a possible role for fetuin-A and osteopontin in patients with juvenile dermatomyositis with calcinosis.
    Marhaug G, Shah V, Shroff R, Varsani H, Wedderburn LR, Pilkington CA, Brogan PA.
    Rheumatology (Oxford); 2008 Jul 11; 47(7):1031-7. PubMed ID: 18448482
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
    Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA.
    Rheumatology (Oxford); 2008 Jun 11; 47(6):877-80. PubMed ID: 18403404
    [Abstract] [Full Text] [Related]

  • 20. Early-onset juvenile dermatomyositis: A tertiary referral center experience and review of the literature.
    Sener S, Basaran O, Batu ED, Sag E, Oz S, Talim B, Bilginer Y, Haliloglu G, Ozen S.
    Semin Arthritis Rheum; 2023 Feb 11; 58():152133. PubMed ID: 36434896
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.